Briefs: CuraTeQ Biologics, Sigachi Industries and Natural Capsules
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The company also reported significant progress toward its internally defined Sustainable Development Goals
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
Growing patent filings and tier-2 innovators reflect expanding national research base
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
Companies in the pharmaceutical industry must shift from L1 (lowest-bid) costing to Life Cycle Cost Analysis (LCCA) to achieve long-term cost optimization, improve decision-making, and enhance sustainability
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Subscribe To Our Newsletter & Stay Updated